GNF-PF-3777
Selleck Chemicals
SKU:E0090-5MG
Couldn't load pickup availability

GNF-PF-3777 is an inhibitor of TDO and IDO1 used in studies of Immune Signaling. It is especially relevant in cancer, immunology, and metabolism models, where defined compound exposure can be linked to cytokine-mediated signaling and inflammatory effector responses.
By inhibiting TDO and IDO1, GNF-PF-3777 can be used to examine cytokine-mediated signaling and inflammatory effector responses. The enzyme annotation adds relevance to enzyme-activity assays, substrate-conversion studies, and mechanism profiling, together with downstream-response mapping in the same experimental setting. In cancer, immunology, and metabolism models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving TDO and IDO1
- Pathway perturbation studies connected to Immune Signaling
- Concentration-response inhibition and target-dependence studies
- Enzyme-activity assays, substrate-conversion studies, and mechanism profiling
Overall, GNF-PF-3777 is appropriate when a defined chemical perturbant is needed to connect TDO and IDO1 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, immunology, and metabolism models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- TDO • IDO1
- Target Class:
- Enzyme
- Pathways:
- Immune Signaling
- Research Area:
- Cancer • Immunology • Metabolism
- CAS No.:
- 77603-42-0
- Molecular Weight:
- 293.23
- Formula:
- C₁₅H₇N₃O₄
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.